Haemonetics (HAE) total debt
Haemonetics (HAE) carried total debt of $1.22B at the end of fiscal 2026 (March 31, 2026). That is level with fiscal 2025. Figures as of 18 Nov 2026, 06:19 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2026
- $1.22B
- Change on fiscal 2025
- −0.0%
- Growth, 5 years
- +11.6% a year
- Growth, 10 years
- +11.6% a year
- Highest on record
- $1.22Bfiscal 2025
- Lowest on record
- $3.77Mfiscal 2012
- Fiscal years on record
- 172010–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Haemonetics total debt, in more detail
Over the five fiscal years to 2026 total debt grew at a compound 11.6% a year; over ten years the rate was 11.6% a year. Across the 17 fiscal years on record (2010–2026), the highest was $1.22B in fiscal 2025 and the lowest $3.77M in fiscal 2012.
Total debt was 1.5× shareholders' equity at the end of fiscal 2026.
Total debt by fiscal year
Haemonetics total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2026 | $1.22B | 0.0% down | 1.5× | |
| 2025 | $1.22B | 51.6% up | 1.5× | |
| 2024 | $807.79M | 5.5% up | 0.8× | |
| 2023 | $765.89M | 1.0% down | 0.9× | |
| 2022 | $773.59M | 9.3% up | 1.0× | |
| 2021 | $707.61M | 85.0% up | 1.0× | |
| 2020 | $382.49M | 9.2% up | 0.7× | |
| 2019 | $350.12M | 38.0% up | 0.5× | |
| 2018 | $253.68M | 19.7% down | 0.3× | |
| 2017 | $315.81M | 22.7% down | 0.4× | |
| 2016 | $408.47M | 5.1% down | 0.6× | |
| 2015 | $430.48M | 2.2% down | 0.5× | |
| 2014 | $440.29M | 9.3% down | 0.5× | |
| 2013 | $485.69M | 12,779.7% up | 0.6× | |
| 2012 | $3.77M | 22.7% down | 0.0× | |
| 2011 | $4.88M | 76.2% down | 0.0× | |
| 2010 | $20.52M | — | 0.0× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Total debt at health care companies of similar size
| Company | Total debt | Fiscal year |
|---|---|---|
| Hims & Hers Health HIMS | $1.12B | 2025 |
| PTC Therapeutics PTCT | $2.71B | 2025 |
| Haemonetics HAE | $1.22B | 2026 |
| Erasca ERAS | $47.14M | 2025 |
| Concentra Group Holdings Parent CON | $2.10B | 2025 |
| Merit Medical Systems MMSI | $821.57M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Haemonetics, figure by figure
- Haemonetics market cap
- Haemonetics revenue
- Haemonetics earnings
- Haemonetics earnings per share (EPS)
- Haemonetics P/E ratio
- Haemonetics P/S ratio
- Haemonetics P/B ratio
- Haemonetics free cash flow
- Haemonetics operating margin
- Haemonetics dividend
- Haemonetics shares outstanding
- Haemonetics cash on hand
- Haemonetics total assets
- Haemonetics return on equity (ROE)
- Haemonetics return on invested capital (ROIC)
Haemonetics (HAE) overview: price, valuation and scorecardAll health care companies by market value
Haemonetics total debt: questions and answers
How much debt does Haemonetics have?
Haemonetics (HAE) carried total debt of $1.22B at the end of fiscal 2026 (March 31, 2026). That is level with fiscal 2025.
What is the growth rate of Haemonetics's total debt?
Over the five fiscal years to 2026 total debt grew at a compound 11.6% a year; over ten years the rate was 11.6% a year.
What are the highest and lowest total debt figures on record for Haemonetics?
Across the 17 fiscal years on record (2010–2026), the highest was $1.22B in fiscal 2025 and the lowest $3.77M in fiscal 2012.
How does Haemonetics's debt compare with its equity?
Total debt was 1.5× shareholders' equity at the end of fiscal 2026.
How is Haemonetics's total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Haemonetics (HAE) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/HAE/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.